Achromatopsia Clinical Trial
Official title:
Clinical and Genetic Characterization of Individuals With Achromatopsia
The purpose of this study is to identify individuals with achromatopsia caused by mutations in the CNGB3 gene and characterize their clinical condition using several tests of visual function every 6 months for up to 1.5 years.
Individuals with a clinical diagnosis of achromatopsia will be asked to provide informed consent and will then have a single 5 mL blood sample drawn for DNA sequence analysis of genes known to cause achromatopsia, including the CNGB3 gene. All participants will be informed of the results of testing for these mutations. Those with mutations in both alleles of the CNGB3 gene will be evaluated every 6 months for up to 1.5 years by using a variety of non-invasive visual function tests to more fully characterize their clinical condition. This testing will include routine ophthalmic examination and tests of visual acuity, color vision, reading speed, perimetry, nystagmus, light sensitivity, optical coherence tomography, adaptive optics retinal imaging, electroretinography, fundus photography and completion of a quality of life questionnaire. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04124185 -
Natural History Study for Achromatopsia
|
||
| Active, not recruiting |
NCT02610582 -
Safety and Efficacy of rAAV.hCNGA3 Gene Therapy in Patients With CNGA3-linked Achromatopsia
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT04041232 -
PBA Use for Treatment of ATF6-/- Patients
|
Early Phase 1 | |
| Active, not recruiting |
NCT03278873 -
Long-Term Follow-Up Gene Therapy Study for Achromatopsia CNGB3 and CNGA3
|
Phase 1/Phase 2 | |
| Recruiting |
NCT02435940 -
Inherited Retinal Degenerative Disease Registry
|
||
| Active, not recruiting |
NCT01648452 -
CNTF Implants for CNGB3 Achromatopsia
|
Phase 1/Phase 2 | |
| Completed |
NCT03001310 -
Gene Therapy for Achromatopsia (CNGB3)
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT02935517 -
Safety and Efficacy Trial of AAV Gene Therapy in Patients With CNGA3 Achromatopsia (A Clarity Clinical Trial)
|
Phase 1/Phase 2 | |
| Completed |
NCT03758404 -
Gene Therapy for Achromatopsia (CNGA3)
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT02599922 -
Safety and Efficacy Trial of AAV Gene Therapy in Patients With CNGB3 Achromatopsia (A Clarity Clinical Trial)
|
Phase 1/Phase 2 |